Loading stock data…
Beta Bionics, Inc. (BBNX)
N/A
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
Historical Price
No chart data available for BBNX
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $27.63M↓ | $32.12M↑ | $27.25M↑ | $23.24M↑ | $17.64M |
| Gross Profit | $16.44M↓ | $18.94M↑ | $15.12M↑ | $12.50M↑ | $8.97M |
| Operating Income | -$24.27M↓ | -$16.12M↑ | -$17.04M↑ | -$19.87M↓ | -$18.64M |
| Net Income | -$21.89M↓ | -$13.47M↑ | -$14.21M↑ | -$16.87M↑ | -$28.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$554.79M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-24.49%
Volume
Today's trading volume
-
Recent News
Beta Bionics to launch its first insulin patch pump to compete with Insulet
The device called Mint, which would work with the company’s adaptive insulin dosing algorithm, is expected to debut in the first half of 2027.
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.
Robert Bruce's Strategic Moves: A Closer Look at Beta Bionics Inc's Impactful Addition
Exploring the Latest 13F Filing and Investment Strategies
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans
Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company’s iLet insulin pump platform. Speaking at a Bank of
Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...